31.33
0.75 (2.45%)
| Penutupan Terdahulu | 30.58 |
| Buka | 31.02 |
| Jumlah Dagangan | 110,178 |
| Purata Dagangan (3B) | 1,890,790 |
| Modal Pasaran | 5,164,312,064 |
| Harga / Pendapatan (P/E TTM) | 14.24 |
| Harga / Pendapatan (P/E Ke hadapan) | 18.18 |
| Harga / Jualan (P/S) | 3.32 |
| Harga / Buku (P/B) | 3.44 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 22 Jul 2025 - 28 Jul 2025 |
| Margin Keuntungan | 23.30% |
| Margin Operasi (TTM) | 4.50% |
| EPS Cair (TTM) | 2.20 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -12.50% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -39.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 5.16% |
| Nisbah Semasa (MRQ) | 3.41 |
| Aliran Tunai Operasi (OCF TTM) | 439.12 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 336.36 M |
| Pulangan Atas Aset (ROA TTM) | 11.62% |
| Pulangan Atas Ekuiti (ROE TTM) | 25.71% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Menurun | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Menurun | Bercampur | |
| Stok | Alkermes plc | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.0 |
| Purata | 0.88 |
|
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.48% |
| % Dimiliki oleh Institusi | 104.81% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Baker Bros. Advisors Lp | 31 Dec 2024 | 4,181,751 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 52.00 (Deutsche Bank, 65.98%) | Beli |
| Median | 40.50 (29.27%) | |
| Rendah | 32.00 (Goldman Sachs, 2.14%) | Beli |
| Purata | 40.67 (29.81%) | |
| Jumlah | 3 Beli, 3 Pegang | |
| Harga Purata @ Panggilan | 33.05 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Baird | 02 May 2025 | 41.00 (30.86%) | Beli | 31.33 |
| UBS | 28 Apr 2025 | 33.00 (5.33%) | Pegang | 27.91 |
| Deutsche Bank | 27 Mar 2025 | 52.00 (65.98%) | Beli | 33.53 |
| 11 Feb 2025 | 40.00 (27.67%) | Beli | 31.96 | |
| RBC Capital | 13 Mar 2025 | 40.00 (27.67%) | Pegang | 33.62 |
| Goldman Sachs | 14 Feb 2025 | 32.00 (2.14%) | Beli | 35.89 |
| HC Wainwright & Co. | 13 Feb 2025 | 46.00 (46.82%) | Pegang | 36.00 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |